Multi Drug Resistant Antibiotics Market, 2012 to 2023
Global Multi-Drug Resistant Antibiotics Market
Market Outline: Multi-Drug Resistant Antibiotics Market
Since the discovery of the penicillin in 1928, large amount of antibiotics are used for human therapy, as well as for farm animals and even for fish in aquaculture, resulted in the selection of pathogenic bacteria resistant to multiple drugs. This multidrug-resistant may be generated by two mechanisms. One is bacteria may accumulate multiple genes, each coding for resistant to the single drug, within a single cell. Another mechanism is increased gene expressions that code for multidrug efflux pumps, effects a wide range of drugs. Multi drug resistant bacteria are formed due to the excessive use of antibiotics in various applications such as prophylactic use for surgery, or immunocompromised patients and other applications. Multi drug resistant antibiotics are the new generation antibiotics that fight against the drug resistant bacteria.
Market Dynamics: Multi-Drug Resistant Antibiotics Market
Multi drug resistant antibiotics market is driven by the increase in prevalence of the drug resistant bacterial infections such as multi drug resistant TB. In addition, increase in R&D activities to develop the new generation multi drug resistant antibiotics by the marketers coupled with the government and non-government organization's initiatives and fundings are expected to boost the market growth over the forecast period. Furthermore, recent drug resistance antibiotic approvals and promising pipeline drugs are expected to bolster the multi drug resistant antibiotics market over the forecast period. However, high cost of R&D and lack of effective antibiotics are expected to hamper the market multi drug resistance antibiotics market during the forecast period.
Market Scope: Multi Drug Resistant Antibiotics Market
Global multi drug resistant antibiotics market is segmented based on type of bacteria, disease and distribution channel
Based on type of bacteria, it is segmented into
Multi Drug Resistant Enterococci
Multi Drug Resistant Staphylococci
Gram Negatives
Others
Based on disease, it is segmented into
Drug Resistant Tuberculosis
Others
Based on distribution channel, it is segmented into
Hospital Pharmacies
Retail Pharmacies
Others
Market Summary: Multi Drug Resistant Antibiotics Market
Emergence of antimicrobial resistance is a major concern, particularly in low and middle-income countries. Multi drug resistance antibiotics market is at growing stage owing to the availability of limited drug resistant antibiotics and there is a huge development need for the novel drugs. The market has many players who are actively participating in the development of the new treatment for multi drug resistant bacterial diseases. For instance, in February 2017, Discuva Ltd., drug discovery company expanded its collaboration with F. Hoffmann-La Roche AG in development of new antibiotic for the life-threatening infections caused by multi drug resistant bacteria and collaboration was originally initiated in February 2014. Furthermore, government and non-government organizations are funding in R&D and spreading awareness related to multi drug resistant antibiotics. Development of novel antibiotics such as plazomicin (in Phase III CL) by Achaogen, Cadazolid (in Phase III CL) by Acetlion Pharmaceuticals and many other companies and their expected commercialization in coming years may drive the market growth furthermore.
Region Anaysis: Multi Drug Resistant Antibiotics Market
Geographically, multi drug resistant antibiotics market has been segmented into Latin America, Europe, Asia- Pacific, North America, and the Middle East & Africa. North America multi drug resistant market is expected to grow at significant rates owing to the factors such as growing awareness and increase in R&D activities in developing the novel drugs for multi drug resistant infections and well-established healthcare infrastructure. Europe market is driven by the increase in prevalence of the multi drug resistant infections and developed healthcare infrastructure. Asia Pacific multi drug resistant market is expected to grow at notable rates owing to low cost of R&D and expansion of the multinational companies into the developing countries such as India.
Market Participants: Multi Drug Resistant Antibiotics Market
Some of the players in Multi-Drug Resistant Antibiotics Market are F. Hoffmann-La Roche AG (Switzerland), Achaogen Inc. (U.S.), Acetlion Pharmaceuticals (Switzerland), Sanofi S.A (France), Johnson & Johnson Servieces Inc. (U.S.), Pfizer Inc. (U.S.), Otsuka Pharmaceutical (Japan), and Eli Lilly and Company (U.S.) to name a few.
Notable Market Developments: Multi Drug Resistant Antibiotics Market
In August 2017, U.S. FDA approved The Medicines Company’s Vabomere (meropenem and vaborbactam) for adult patients with urinary tract infections, including pyelonephritis. Vabomere also inhibits certain types of resistance mechanisms used by bacteria
In May 2014, U.S. FDA approved Durata Therapeutic’s (acquired by Actavis) Dalvance (dalbavancin), new anti-bacterial drug for the methicillin-resistant Staphylococcus aureus (MRSA) infections
Key Features of the Report
The report provides granular level information about The market size, regional market share and forecast from 2017-2023
The report covers in-detail insights about The competitor’s overview, key findings and Their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by The industry
The report tracks recent innovations, key developments and startup’s details that are working in The industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
Market Outline: Multi-Drug Resistant Antibiotics Market
Since the discovery of the penicillin in 1928, large amount of antibiotics are used for human therapy, as well as for farm animals and even for fish in aquaculture, resulted in the selection of pathogenic bacteria resistant to multiple drugs. This multidrug-resistant may be generated by two mechanisms. One is bacteria may accumulate multiple genes, each coding for resistant to the single drug, within a single cell. Another mechanism is increased gene expressions that code for multidrug efflux pumps, effects a wide range of drugs. Multi drug resistant bacteria are formed due to the excessive use of antibiotics in various applications such as prophylactic use for surgery, or immunocompromised patients and other applications. Multi drug resistant antibiotics are the new generation antibiotics that fight against the drug resistant bacteria.
Market Dynamics: Multi-Drug Resistant Antibiotics Market
Multi drug resistant antibiotics market is driven by the increase in prevalence of the drug resistant bacterial infections such as multi drug resistant TB. In addition, increase in R&D activities to develop the new generation multi drug resistant antibiotics by the marketers coupled with the government and non-government organization's initiatives and fundings are expected to boost the market growth over the forecast period. Furthermore, recent drug resistance antibiotic approvals and promising pipeline drugs are expected to bolster the multi drug resistant antibiotics market over the forecast period. However, high cost of R&D and lack of effective antibiotics are expected to hamper the market multi drug resistance antibiotics market during the forecast period.
Market Scope: Multi Drug Resistant Antibiotics Market
Global multi drug resistant antibiotics market is segmented based on type of bacteria, disease and distribution channel
Based on type of bacteria, it is segmented into
Multi Drug Resistant Enterococci
Multi Drug Resistant Staphylococci
Gram Negatives
Others
Based on disease, it is segmented into
Drug Resistant Tuberculosis
Others
Based on distribution channel, it is segmented into
Hospital Pharmacies
Retail Pharmacies
Others
Market Summary: Multi Drug Resistant Antibiotics Market
Emergence of antimicrobial resistance is a major concern, particularly in low and middle-income countries. Multi drug resistance antibiotics market is at growing stage owing to the availability of limited drug resistant antibiotics and there is a huge development need for the novel drugs. The market has many players who are actively participating in the development of the new treatment for multi drug resistant bacterial diseases. For instance, in February 2017, Discuva Ltd., drug discovery company expanded its collaboration with F. Hoffmann-La Roche AG in development of new antibiotic for the life-threatening infections caused by multi drug resistant bacteria and collaboration was originally initiated in February 2014. Furthermore, government and non-government organizations are funding in R&D and spreading awareness related to multi drug resistant antibiotics. Development of novel antibiotics such as plazomicin (in Phase III CL) by Achaogen, Cadazolid (in Phase III CL) by Acetlion Pharmaceuticals and many other companies and their expected commercialization in coming years may drive the market growth furthermore.
Region Anaysis: Multi Drug Resistant Antibiotics Market
Geographically, multi drug resistant antibiotics market has been segmented into Latin America, Europe, Asia- Pacific, North America, and the Middle East & Africa. North America multi drug resistant market is expected to grow at significant rates owing to the factors such as growing awareness and increase in R&D activities in developing the novel drugs for multi drug resistant infections and well-established healthcare infrastructure. Europe market is driven by the increase in prevalence of the multi drug resistant infections and developed healthcare infrastructure. Asia Pacific multi drug resistant market is expected to grow at notable rates owing to low cost of R&D and expansion of the multinational companies into the developing countries such as India.
Market Participants: Multi Drug Resistant Antibiotics Market
Some of the players in Multi-Drug Resistant Antibiotics Market are F. Hoffmann-La Roche AG (Switzerland), Achaogen Inc. (U.S.), Acetlion Pharmaceuticals (Switzerland), Sanofi S.A (France), Johnson & Johnson Servieces Inc. (U.S.), Pfizer Inc. (U.S.), Otsuka Pharmaceutical (Japan), and Eli Lilly and Company (U.S.) to name a few.
Notable Market Developments: Multi Drug Resistant Antibiotics Market
In August 2017, U.S. FDA approved The Medicines Company’s Vabomere (meropenem and vaborbactam) for adult patients with urinary tract infections, including pyelonephritis. Vabomere also inhibits certain types of resistance mechanisms used by bacteria
In May 2014, U.S. FDA approved Durata Therapeutic’s (acquired by Actavis) Dalvance (dalbavancin), new anti-bacterial drug for the methicillin-resistant Staphylococcus aureus (MRSA) infections
Key Features of the Report
The report provides granular level information about The market size, regional market share and forecast from 2017-2023
The report covers in-detail insights about The competitor’s overview, key findings and Their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by The industry
The report tracks recent innovations, key developments and startup’s details that are working in The industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
1. EXECUTIVE SUMMARY
2. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET INTRODUCTION
2.1. Global Multi Drug Resistant Antibiotics Market – Taxonomy
2.2. Global Multi Drug Resistant Antibiotics Market –Definitions
2.2.1. Type of Bacteria
2.2.2. Distribution Channel
3. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Multi Drug Resistant Antibiotics Market Dynamics – Factors Impact Analysis
3.6. Global Multi Drug Resistant Antibiotics Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Multi Drug Resistant Antibiotics Market – Product Innovations
4. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET, BY TYPE OF BACTERIA, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Type of Bacteria Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
5.1.1. Multi Drug Resistant Enterococci
5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.1.3. Market Opportunity Analysis
5.1.2. Multi Drug Resistant Staphylococci
5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.2.3. Market Opportunity Analysis
5.1.3. Gram Negatives
5.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3.3. Market Opportunity Analysis
5.1.4. Others
5.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.4.3. Market Opportunity Analysis
6. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET FORECAST, BY DISEASE, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Drug Resistant Tuberculosis
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Others
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
7. MARKET OPPORTUNITY ANALYSIS GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
8. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
8.6. Global Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Disease Type, End User, and Region, 2017 – 2023
9. NORTH AMERICA MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Type of Bacteria Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Multi Drug Resistant Enterococci
9.1.1.2. Multi Drug Resistant Staphylococci
9.1.1.3. Gram Negatives
9.1.1.4. Others
9.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. Drug Resistant Tuberculosis
9.1.2.2. Others
9.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Hospital Pharmacies
9.1.3.2. Retail Pharmacies
9.1.3.3. Others
9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Disease, End User and Country, 2017 – 2023
9.1.6. North America Multi Drug Resistant Antibiotics Market Dynamics – Trends
10. EUROPE MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Type of Bacteria Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Multi Drug Resistant Enterococci
10.1.1.2. Multi Drug Resistant Staphylococci
10.1.1.3. Gram Negatives
10.1.1.4. Others
10.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Drug Resistant Tuberculosis
10.1.2.2. Others
10.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Hospital Pharmacies
10.1.3.2. Retail Pharmacies
10.1.3.3. Others
10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Distribution Channel, and Country, 2017 – 2023
10.1.6. Europe Multi Drug Resistant Antibiotics Market Dynamics – Trends
11. ASIA-PACIFIC MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Type of Bacteria Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Multi Drug Resistant Enterococci
11.1.1.2. Multi Drug Resistant Staphylococci
11.1.1.3. Gram Negatives
11.1.1.4. Others
11.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Drug Resistant Tuberculosis
11.1.2.2. Others
11.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Hospital Pharmacies
11.1.3.2. Retail Pharmacies
11.1.3.3. Others
11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Japan
11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Distribution Channel, and Country, 2017 – 2023
11.1.6. Europe Multi Drug Resistant Antibiotics Market Dynamics – Trends
12. LATIN AMERICA MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Type of Bacteria Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Multi Drug Resistant Enterococci
12.1.1.2. Multi Drug Resistant Staphylococci
12.1.1.3. Gram Negatives
12.1.1.4. Others
12.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Drug Resistant Tuberculosis
12.1.2.2. Others
12.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Hospital Pharmacies
12.1.3.2. Retail Pharmacies
12.1.3.3. Others
12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Distribution Channel, and Country, 2017 – 2023
12.1.6. Latin America Multi Drug Resistant Antibiotics Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Type of Bacteria Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1.1. Multi Drug Resistant Enterococci
13.1.1.2. Multi Drug Resistant Staphylococci
13.1.1.3. Gram Negatives
13.1.1.4. Others
13.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. Drug Resistant Tuberculosis
13.1.2.2. Others
13.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Hospital Pharmacies
13.1.3.2. Retail Pharmacies
13.1.3.3. Others
13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Gulf Cooperation Council (GCC) Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Distribution Channel, and Country, 2017 – 2023
13.1.6. MEA Multi Drug Resistant Antibiotics Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Achaogen, Inc (U.S.)
14.2.2. Actelion Pharmaceuticals (Switzerland)
14.2.3. GlaxoSmithKline Plc (U.K.)
14.2.4. F. Hoffmann La Roche (Switzerland)
14.2.5. Eli Lilly and Company (U.S.)
14.2.6. Sanofi S.A. (France)
14.2.7. Johnson & Johnson Services Inc., (U.S.)
14.2.8. Pfizer Inc., (U.S.)
14.2.9. Otsuka pharmaceutical (Japan)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET INTRODUCTION
2.1. Global Multi Drug Resistant Antibiotics Market – Taxonomy
2.2. Global Multi Drug Resistant Antibiotics Market –Definitions
2.2.1. Type of Bacteria
2.2.2. Distribution Channel
3. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Multi Drug Resistant Antibiotics Market Dynamics – Factors Impact Analysis
3.6. Global Multi Drug Resistant Antibiotics Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Multi Drug Resistant Antibiotics Market – Product Innovations
4. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET, BY TYPE OF BACTERIA, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Type of Bacteria Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
5.1.1. Multi Drug Resistant Enterococci
5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.1.3. Market Opportunity Analysis
5.1.2. Multi Drug Resistant Staphylococci
5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.2.3. Market Opportunity Analysis
5.1.3. Gram Negatives
5.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3.3. Market Opportunity Analysis
5.1.4. Others
5.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.4.3. Market Opportunity Analysis
6. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET FORECAST, BY DISEASE, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Drug Resistant Tuberculosis
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Others
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
7. MARKET OPPORTUNITY ANALYSIS GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
8. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
8.6. Global Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Disease Type, End User, and Region, 2017 – 2023
9. NORTH AMERICA MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Type of Bacteria Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Multi Drug Resistant Enterococci
9.1.1.2. Multi Drug Resistant Staphylococci
9.1.1.3. Gram Negatives
9.1.1.4. Others
9.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. Drug Resistant Tuberculosis
9.1.2.2. Others
9.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Hospital Pharmacies
9.1.3.2. Retail Pharmacies
9.1.3.3. Others
9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Disease, End User and Country, 2017 – 2023
9.1.6. North America Multi Drug Resistant Antibiotics Market Dynamics – Trends
10. EUROPE MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Type of Bacteria Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Multi Drug Resistant Enterococci
10.1.1.2. Multi Drug Resistant Staphylococci
10.1.1.3. Gram Negatives
10.1.1.4. Others
10.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Drug Resistant Tuberculosis
10.1.2.2. Others
10.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Hospital Pharmacies
10.1.3.2. Retail Pharmacies
10.1.3.3. Others
10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Distribution Channel, and Country, 2017 – 2023
10.1.6. Europe Multi Drug Resistant Antibiotics Market Dynamics – Trends
11. ASIA-PACIFIC MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Type of Bacteria Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Multi Drug Resistant Enterococci
11.1.1.2. Multi Drug Resistant Staphylococci
11.1.1.3. Gram Negatives
11.1.1.4. Others
11.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Drug Resistant Tuberculosis
11.1.2.2. Others
11.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Hospital Pharmacies
11.1.3.2. Retail Pharmacies
11.1.3.3. Others
11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Japan
11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Distribution Channel, and Country, 2017 – 2023
11.1.6. Europe Multi Drug Resistant Antibiotics Market Dynamics – Trends
12. LATIN AMERICA MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Type of Bacteria Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Multi Drug Resistant Enterococci
12.1.1.2. Multi Drug Resistant Staphylococci
12.1.1.3. Gram Negatives
12.1.1.4. Others
12.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Drug Resistant Tuberculosis
12.1.2.2. Others
12.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Hospital Pharmacies
12.1.3.2. Retail Pharmacies
12.1.3.3. Others
12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Distribution Channel, and Country, 2017 – 2023
12.1.6. Latin America Multi Drug Resistant Antibiotics Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Type of Bacteria Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1.1. Multi Drug Resistant Enterococci
13.1.1.2. Multi Drug Resistant Staphylococci
13.1.1.3. Gram Negatives
13.1.1.4. Others
13.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. Drug Resistant Tuberculosis
13.1.2.2. Others
13.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Hospital Pharmacies
13.1.3.2. Retail Pharmacies
13.1.3.3. Others
13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Gulf Cooperation Council (GCC) Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Distribution Channel, and Country, 2017 – 2023
13.1.6. MEA Multi Drug Resistant Antibiotics Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Achaogen, Inc (U.S.)
14.2.2. Actelion Pharmaceuticals (Switzerland)
14.2.3. GlaxoSmithKline Plc (U.K.)
14.2.4. F. Hoffmann La Roche (Switzerland)
14.2.5. Eli Lilly and Company (U.S.)
14.2.6. Sanofi S.A. (France)
14.2.7. Johnson & Johnson Services Inc., (U.S.)
14.2.8. Pfizer Inc., (U.S.)
14.2.9. Otsuka pharmaceutical (Japan)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS